Conclusion As of 2025, there is no FDA-approved generic version of Mounjaro available in the United States. While compounded tirzepatide has been offered by some pharmacies, it is not a generic drug and lacks the rigorous safety, quality, and efficacy reviews of FDA-approved medications. There is no generic version of Mounjaro currently available, and one might not be available until at least the early 2030s.

Understanding the Context

The manufacturer, Eli Lilly, currently holds patent rights that prevent other companies from making a generic. Neither one is available as a generic. While they work in similar ways and are approved for similar indications, they are different drugs. There is no Mounjaro generic.

Key Insights

The 2 different brands of tirzepatide (Mounjaro and Zepbound) are made by Eli Lilly and Company but are FDA-approved for different conditions. No, Mounjaro doesn’t have a generic version available yet. If you see places advertising that they sell “generic Mounjaro” or “generic tirzepatide,” they may be selling counterfeit medication. No generic version of Mounjaro (Tirzepatide) currently exists due to ongoing patent protection. Patients should obtain Mounjaro from reputable sources like healthcare providers or licensed pharmacies to avoid counterfeit or illegal versions.

Final Thoughts

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be . This may change due to patent challenges or generic licensing. When will the patents on MOUNJARO expire, and when will generic ...